Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Inmune Bio, Inc.INMB · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $32.4M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | thin data, degenerate inputs · fortress balance sheetnot computable: short runway, distress |
| Inputs computable | 6 of 14 |
| Graded from | filings received through Mar 30, 2026193 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $1.842026-10-08; market equity $51.2M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.
Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction Program: CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom, our proprietary, pooled, human umbilical cord-derived mesenchymal stromal cell platform. RDEB is a devastating pediatric orphan disease caused by mutations in the COL7A1 gene.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 6.7 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| required facts have no common fiscal period end | |||||||
| Accruals ratio | (64.9%) | [1,5-7] | (6.6%) | 6.7 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 63.8 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (23.76) | [1,8-13] | (0.31) | 76.3 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| required facts have no common fiscal period end | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 3.55x | [8-9] | 2.96x | 51.3 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 81.1 | |||||||
| Revenue growth, three-year compound | (48.9%) | [2,14-16] | 10.0% | 95.7 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| four consecutive annual FCF observations are required; found 1 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| required facts have no common fiscal period end | |||||||
| Asset growth, three years | (26.6%) | [1,7,17-18] | 2.1% | 90.6 | 704 | 2025-12-31 | |
| Net share issuance, one year | 15.9% | [19-20] | 2.5% | 57.0 | 634 | 2026-03-30 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 11.1% | 8.0% | 52 | hotter than 52 of 100 peers |
| Distance from 52-week high | (27.1%) | (31.4%) | 56 | closer to its high than 56 of 100 peers |
| EBIT to enterprise value | (115.5%) | (1.5%) | 5 | pricier than 95 of 100 peers |
| Free cash flow yield | (46.5%) | (1.0%) | 13 | pricier than 87 of 100 peers |
| Book value to price | 0.40 | 0.28 | 62 | pricier than 38 of 100 peers |
| Sales to price | 0.00 | 0.31 | 3 | pricier than 97 of 100 peers |
| Composite equity issuance, five years | 62.0% | 20.3% | 69 | more equity-funded than 69 of 100 peers |
| Relative strength against the sector, log excess return | (0.11) | (0.14) | 52 | ahead of 52 of 100 peers |
Inputs: market equity $50.8M; EBIT -$47.4M; free cash flow -$23.6M; book equity $20.4M; sales $50,000; debt $15.0M; cash $24.8M[21].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (116.1%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$22.6M | ✗ fail[6] |
| Return on assets improved | (42.3 pts) | ✗ fail[5,7,17,22] |
| Operating cash flow exceeds net income | $23.4M | ✓ pass[5-6] |
| Long-term leverage fell | n/a[1,4,7,17] | |
| Current ratio improved | 41.3 pts | ✓ pass[8-9,23-24] |
| No new shares issued | 15.9% | ✗ fail[19-20] |
| Gross margin improved | n/a | |
| Asset turnover improved | 0.1 pts | ✓ pass[2,7,14,17] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a[6,25-28] |
| Months of runway | not finite |
| cash is missing at the end of the latest cash-flow quarter | |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 64 |
| 10-Q received Aug 6, 2026 | |
| Median daily dollar volume | $693,885 |
| 63 sessions | |
| Days since newest grade input | 193 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $32.4M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:Revenues | $50,000 | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $20.9M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 4 | total debt | us-gaap:LongTermDebt | $15.0M | 2024-12-31 | 2025-03-27 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$45.9M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$22.6M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $39.6M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 8 | current assets | us-gaap:AssetsCurrent | $29.9M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $8.4M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$209.0M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$47.4M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 12 | book equity | us-gaap:StockholdersEquity | $23.5M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 13 | liabilities | us-gaap:Liabilities | $8.8M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 14 | revenue | us-gaap:Revenues | $14,000 | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:Revenues | $155,000 | 2023-12-31 | 2025-03-27 | 10-K | filing · viewer · series |
| 16 | revenue | us-gaap:Revenues | $374,000 | 2022-12-31 | 2024-03-28 | 10-K | filing · viewer · series |
| 17 | assets | us-gaap:Assets | $57.0M | 2023-12-31 | 2025-03-27 | 10-K | filing · viewer · series |
| 18 | assets | us-gaap:Assets | $81.8M | 2022-12-31 | 2024-03-28 | 10-K | filing · viewer · series |
| 19 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 26,585,258 | 2026-03-30 | 2026-03-30 | 10-K | filing · viewer · series |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 22,930,311 | 2025-03-27 | 2025-03-27 | 10-K | filing · viewer · series |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 27,753,789 | 2026-08-06 | 2026-08-06 | 10-Q | filing · viewer · series |
| 22 | net income | us-gaap:NetIncomeLoss | -$42.1M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 23 | current assets | us-gaap:AssetsCurrent | $22.7M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 24 | current liabilities | us-gaap:LiabilitiesCurrent | $7.2M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$6.6M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$3.4M | 2026-03-31 | 2026-05-07 | 10-Q | filing · viewer · series |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$19.6M | 2025-09-30 | 2025-10-30 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$14.2M | 2025-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
